摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one

中文名称
——
中文别名
——
英文名称
4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one
英文别名
4-amino-3-bromo-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrazolo[3,4-d]pyrimidin-6-one
4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one化学式
CAS
——
化学式
C11H14BrN5O5
mdl
——
分子量
376.167
InChiKey
QYLMQEGSERMXEH-BHBWVORQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    144
  • 氢给体数:
    4
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    磷酸三甲酯 、 4-amino-3-bromo-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one 在 sodium hydroxide 作用下, 以 为溶剂, 反应 20.0h, 以32%的产率得到4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one
    参考文献:
    名称:
    与2-氨基腺苷和异鸟苷有关的吡唑并[3,4-d]嘧啶核糖核苷:合成,脱氨基和互变异构。
    摘要:
    描述了与2-氨基腺苷和异鸟苷相关的8-氮杂-7-脱氮嘌呤(吡唑并[3,4-d]嘧啶)核糖核苷的合成和性质。在BF(3)存在下,将1-氮-乙酰基2,3,5-三-O-苯甲酰基-β-D-呋喃呋喃糖与8-氮杂7-脱氮嘌呤-2,6-二胺5糖基化。 )x Et(2)O作为催化剂,得到N(8)异构体14(73%)和痕量的N(9)异构体13a(4.8%)。在相同的反应条件下,7-卤代8-氮杂-7-脱氮嘌呤-2,6-二胺6-8提供了热力学上更稳定的N(9)核苷13b-d作为唯一产物(53-70%)。因此,位置7的卤素将糖基化作用从N(8)转移到N(9)。通过2-氨基的重氮化将8-氮杂-7-脱氮嘌呤-4,6-二胺核糖核苷1a-d转化为异鸟苷衍生物3a-d。尽管化合物1a b。在7位(酶结合位点)不含氮,它们被腺苷脱氨酶脱氨;但是,它们的脱氨速度比相关嘌呤的速度要慢得多。pK(a)值表明,将7个非功能化核苷1a(pK(a)5
    DOI:
    10.1039/b708736e
点击查看最新优质反应信息

文献信息

  • Pyrazolo[3,4-d]pyrimidine ribonucleosides related to 2-aminoadenosine and isoguanosine: synthesis, deamination and tautomerism
    作者:Frank Seela、Kuiying Xu
    DOI:10.1039/b708736e
    日期:——
    than that of the related purines. The pK(a) values indicate that the 7-non-functionalized nucleosides 1a (pK(a) 5.8) and 15 (pK(a) 6.4) are possibly protonated in neutral conditions when incorporated into RNA. The nucleosides 3a-d exist predominantly in the keto (lactam) form with K(TAUT) (keto/enol) values of 400-1200 compared to 10(3)-10(4) for pyrrolo[2,3-d]pyrimidine isoguanosine derivatives 4a-c
    描述了与2-氨基腺苷和异鸟苷相关的8-氮杂-7-脱氮嘌呤(吡唑并[3,4-d]嘧啶)核糖核苷的合成和性质。在BF(3)存在下,将1-氮-乙酰基2,3,5-三-O-苯甲酰基-β-D-呋喃呋喃糖与8-氮杂7-脱氮嘌呤-2,6-二胺5糖基化。 )x Et(2)O作为催化剂,得到N(8)异构体14(73%)和痕量的N(9)异构体13a(4.8%)。在相同的反应条件下,7-卤代8-氮杂-7-脱氮嘌呤-2,6-二胺6-8提供了热力学上更稳定的N(9)核苷13b-d作为唯一产物(53-70%)。因此,位置7的卤素将糖基化作用从N(8)转移到N(9)。通过2-氨基的重氮化将8-氮杂-7-脱氮嘌呤-4,6-二胺核糖核苷1a-d转化为异鸟苷衍生物3a-d。尽管化合物1a b。在7位(酶结合位点)不含氮,它们被腺苷脱氨酶脱氨;但是,它们的脱氨速度比相关嘌呤的速度要慢得多。pK(a)值表明,将7个非功能化核苷1a(pK(a)5
查看更多

同类化合物

别嘌呤醇核糖苷 [3,4-二乙酰氧基-5-(5-甲硫基-2,4,8,9-四氮杂双环[4.3.0]壬-2,4,7,10-四烯-9-基)四氢呋喃-2-基]甲基乙酸酯 4-氨基-3-苄基-1H-吡唑并[3,4-d]嘧啶-1-β-D-呋喃核糖 1 beta-呋喃核糖基-4-(甲硫基)吡唑并(3,4-d)嘧啶 4-amino-3-bromo-6-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one 8-aza-7-deaza-7-propynyladenosine 1-(β-D-ribofuranosyl)-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-3-carboxy-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 4-amino-1-(α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 2-(5-Amino-4-iminopyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;hydrochloride 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-carboxamidine 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-piperidino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4-methoxy-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran- 2-yl]-1H-pyrazolo[3,4-d]pyrimidine-3-carboximidoate 4-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine 4-amino-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine-3-carbonitrile 4-amino-1-(β-D-ribofuranosyl)-3-[2-(methoxycarbonyl)ethenyl]-1H-pyrazolo[3,4-d]pyrimidine 1-Pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine 4-Amino-1-pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidine-3-carbonitrile 4-Amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidamide Methyl 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidate 1H-Pyrazolo[3, 4-amino-1-beta-D-ribofuranosyl-, hydrazide, hemihydrate 2-(Hydroxymethyl)-5-[4-(methylamino)pyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-beta-D-ribofuranosyl-4-methoxypyrazolo[3,4-d] pyrimidine 2-[4-(Dimethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 4-{[(4-Nitrophenyl)methyl]sulfanyl}-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidine 2-(4-Hydrazinylpyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol [5-[4-(Benzylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate 2-(Hydroxymethyl)-5-(4-prop-2-enylsulfanylpyrazolo[3,4-d]pyrimidin-1-yl)oxolane-3,4-diol N-Benzyl-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(Hydroxymethyl)-5-pyrazolo[3,4-d]pyrimidin-1-yloxolane-3,4-diol [5-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate [3,4-Diacetyloxy-5-(4-anilinopyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-Pentofuranosyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [3,4-Diacetyloxy-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 2-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-[4-(Hydroxyamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-(Hydroxymethyl)-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-[4-(aziridin-1-yl)pyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 1-(β-D-ribofuranosyl)-4,6-bis(chlorodifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-4,6-bis(difluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine